arrow
C

Carrie A. Thompson

Mayo Clinic
H指数:46
被引数:7,327

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival trends in Waldenström macroglobulinemia and comparison of outcomes with the general United States population

华氏巨球蛋白血症的生存趋势及与全美普通人群结局的比较

Leukemia
IF13.4
2026-11-120
PRE
Perinatal and Early-Life Exposures and Risk of Non-Hodgkin Lymphoma

围产期和早期生命暴露与非霍奇金淋巴瘤风险

Cancers
IF4.4
2026-08-280
OA
Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes

血液恶性肿瘤家族史与非霍奇金淋巴瘤亚型的预后关系

2026-03-100
OA
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study
2025-11-010
PRE
Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort

自评生成的Charlson合并症指数在淋巴瘤结局流行病学(LEO)队列中的适应性和表现

2025-10-070
PRE
PROs versus clinician-reported adverse events in a large clinical trial: findings from the Phase 3 POLARIX study

患者报告结果(PROs)与临床医生报告的不良事件在大型临床试验中的比较:来自III期POLARIX研究的结果

Blood
IF23.1
2025-09-290
OA
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature

边缘区淋巴瘤的转化:一项前瞻性队列研究及文献荟萃分析的结果

2024-11-270
OAAI
Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screening

偶然诊断的弥漫性大b细胞淋巴瘤的特征和结果以及对癌症筛查的意义

2024-10-140
OAAI
The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events

继发于waldenstr ö m巨球蛋白血症的获得性血管性血友病综合征的临床影响: 主要出血事件的一个未被充分认识的来源

LEUKEMIA
IF13.4
2024-08-280
PRE
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

淋巴瘤结局流行病学队列研究: 设计、基线特征和早期结局

2024-01-136
PRE